DSCC1 and lymphoma: Dscc1 mutants displayed significantly decreased tumour latency (P < 0.0014, log-rank test), with lymphoma being the predominant malignancy (Fig. 2e), therefore suggesting that DSCC1 can act as a tumour suppressor.